ReviewBMC infectious diseases2025
Gordonia bronchialis: an emerging opportunistic pathogen-a case report and comprehensive review.
Review in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGordonia bronchialis (G. bronchialis) is an emerging opportunistic pathogen that primarily affects immunocompromised individuals and is often associated with indwelling catheters. CASE PRESENTATION: This paper presents a case of central line-associated bloodstream infection caused by G. bronchialis in a 15-year-old male with acute myeloid leukemia (AML), highlighting diagnostic challenges and successful treatment with antimicrobial therapy. The isolate was identified as G. bronchialis using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Subsequent antimicrobial susceptibility testing revealed it to be susceptible to amikacin, amoxicillin-clavulanate, ceftriaxone, ciprofloxacin, clarithromycin, imipenem, linezolid, minocycline, moxifloxacin, trimethoprim-sulfamethoxazole, tobramycin, cefepime, cefotaxime and doxycycline. A comprehensive literature review of 41 reported cases underscores the diverse clinical manifestations of G. bronchialis infections, including bacteremia, sternal wound infections, and osteomyelitis, with a 95.1% cure rate. Diagnostic limitations and the need for advanced microbiological techniques are discussed, emphasizing the importance of clinical awareness in immunocompromised patients.
conclusionsThis review advocates for standardized treatment guidelines and further research into virulence mechanisms and biofilm-disrupting agents to combat this pathogen effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.